REBYOTA医薬品の考察と市場予測 - 2032年

当レポートでは、REBYOTA医薬品の主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 クロストリジウムディフィシル感染症におけるREBYOTAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 REBYOTA市場の評価

• クロストリジウムディフィシル感染症におけるREBYOTAの市場見通し
• 主要7市場の分析
  • 主要7市場のクロストリジウムディフィシル感染症向けREBYOTAの市場規模
• 市場の分析：国別
  • 米国のクロストリジウムディフィシル感染症向けREBYOTAの市場規模
  • ドイツのクロストリジウムディフィシル感染症向けREBYOTAの市場規模
  • 英国のクロストリジウムディフィシル感染症向けREBYOTAの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: REBYOTA, Clinical Trial Description, 2023
• Table 2: REBYOTA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: REBYOTA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: REBYOTA Market Size in the US, in USD million (2019-2032)
• Table 7: REBYOTA Market Size in Germany, in USD million (2019-2032)
• Table 8: REBYOTA Market Size in France, in USD million (2019-2032)
• Table 9: REBYOTA Market Size in Italy, in USD million (2019-2032)
• Table 10: REBYOTA Market Size in Spain, in USD million (2019-2032)
• Table 11: REBYOTA Market Size in the UK, in USD million (2019-2032)
• Table 12: REBYOTA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: REBYOTA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: REBYOTA Market Size in the United States, USD million (2019-2032)
• Figure 3: REBYOTA Market Size in Germany, USD million (2019-2032)
• Figure 4: REBYOTA Market Size in France, USD million (2019-2032)
• Figure 5: REBYOTA Market Size in Italy, USD million (2019-2032)
• Figure 6: REBYOTA Market Size in Spain, USD million (2019-2032)
• Figure 7: REBYOTA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: REBYOTA Market Size in Japan, USD million (2019-2032)

“"REBYOTA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REBYOTA for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the REBYOTA for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REBYOTA for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REBYOTA market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

REBYOTA (RBX2660), being developed by Ferring Pharmaceuticals, is a first-in-class microbiota-based live biotherapeutic product to deliver a broad consortium of diverse microbes to the gut to reduce rCDI after antibiotic treatment.

Ferring Pharmaceuticals reported successful results from the Phase III PUNCH CD3 clinical trial demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing the recurrence of CDI over placebo.

The company has leveraged its clinical, manufacturing, and regulatory experience with RBX2660 to develop a lyophilized non-frozen oral capsule formulation RBX7455. Ferring plans on conducting a Phase III study of RBX7455, which enhances the clinical pipeline of human microbiome-directed drug candidates.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the REBYOTA description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on REBYOTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the REBYOTA research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around REBYOTA.
• The report contains forecasted sales of REBYOTA for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for REBYOTA in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REBYOTA Analytical Perspective by DelveInsight

In-depth REBYOTA Market Assessment

This report provides a detailed market assessment of REBYOTA for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

REBYOTA Clinical Assessment

The report provides the clinical trials information of REBYOTA for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REBYOTA dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to REBYOTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REBYOTA in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of REBYOTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REBYOTA in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of REBYOTA?
• What is the clinical trial status of the study related to REBYOTA in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REBYOTA development?
• What are the key designations that have been granted to REBYOTA for clostridium difficile infection?
• What is the forecasted market scenario of REBYOTA for clostridium difficile infection?
• What are the forecasted sales of REBYOTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to REBYOTA for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. REBYOTA Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. REBYOTA Market Assessment

• 5.1. Market Outlook of REBYOTA in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of REBYOTA in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of REBYOTA in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of REBYOTA in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of REBYOTA in France for Clostridium difficile infection
  • 5.3.4. Market Size of REBYOTA in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of REBYOTA in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of REBYOTA in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of REBYOTA in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options